A somatic point mutation in the tyrosine kinase JAK2 (1849 G to T) has been described in myeloproliferative diseases (MPD), resulting in a non-synonymous amino-acid substitution (V to F) at position 617. This mutation (JAK2V617F) is located in the JH2 pseudo-kinase auto-inhibitory domain, rendering the enzyme constitutively active and leading to cytokine hypersensitivity and erythrocytosis in mice. 1 There is considerable variation in the reports of JAK2V617F frequency in MPD, with incidence rates of 23-57% in essential thrombocythemia, 35-57% in idiopathic myelofibrosis and 65-97% in polycythemia vera (PV). 2 Of particular interest is the expression of JAK2V617F mutation in PV, with its hallmark of erythrocytosis, which involves the JAK2-signaling pathway. Possible reasons for discrepancies in the observed mutation frequency in PV by different research groups include (1) differences in assay sensitivity, 3 (2) diagnostic inaccuracy and (3) treatment effect. 4 In order to examine these possibilities, we have re-examined 17 previously published JAK2V617F-negative PV cases, including nine from the Mayo Clinic, 5, 6 four from the MD Anderson Cancer Center (MDACC) 7 and four from the Weill Medical College. 8 Among the nine Mayo Clinic cases, the diagnosis was inaccurate in four and questionable in one. Repeat testing with more sensitive techniques revealed the presence of the mutation in three of the remaining four patients. In the last patient, there was not enough material for re-testing. Among the four MDACC cases, two were positive for JAK2V617F mutation on re-testing using a more sensitive technique; mutation screening in the other two patients was performed at the time of leukemic transformation and the historical diagnosis of PV had not been well documented. Of the four cases reported by the Weill Medical College researchers, two were receiving interferon-a therapy for several years before testing for the mutation, and two had interferon discontinued 2 years before testing for JAK2 because of excellent clinical response. Thus, treatment could have resulted in the suppression of the mutant clone. 4 Therefore, we conclude that a diagnosis of 'PV' in the absence of the JAK2V617F warrants a re-evaluation that takes into account the possibility for misdiagnosis, treatment-related effect and an insufficiently sensitive mutation screening assay. Once these three issues are addressed, it seems likely that the JAK2V617F mutation may be present in virtually all PV patients.
